Structural abnormalities
Open neural tube defects such as anencephaly and open spina bifida allow cc fetoprotein to escape from cerebral spinal fluid into the amniotic fluid, whence it is absorbed into the maternal blood, producing higher than normal concentrations. This is the basis of a fetoprotein screening performed between 14 and 16 weeks. It is virtually non-invasive, entailing only taking a blood sample, and has a high predictive value. Fetal gestational age must be estimated by ultrasonography. False positive results can be caused by multiple pregnancy, a dead fetus, bleeding behind the placenta (which may manifest as a threatened abortion), and a few rather rarer abnormalities of the fetus such as gastroschisis.
If the serum cc fetoprotein concentration is high either an amniotic fluid sample can be obtained by amniocentesis or a special ultrasound scan is performed to examine the spine and head carefully at 18-19 weeks of gestation.
Maternal serum (x fetoprotein concentration by weeks of gestation. The upper line is taken as the boundary of the normal group, so it is important to date the pregnancy precisely-that is, by ultrasound measurement of the biparietal diameter. By 20 weeks the fetus can be seen clearly on ultrasonography and many neural tube defects will have been determined. A little later the heart can be examined and the four chambers identified so that major cardiac abnormalities can be excluded. Limbs can be seen to exclude any shortening and, if relevant, the sex of the child may be determined by presence of the external genitalia in the male. 
Availability of tests
Biochemical screening for abnormalities of the central nervous system and for Down's syndrome is patchy and varies from one district health authority to another. The reasons lie not just in the whims of economic dictate but with variations in the interpretation of epidemiological data. 
Abnormalities ofthe central nervous system
The total number of abnormalities of the central nervous system in England and Wales has fallen since the early 1970s. Data are based on three sources: * Notification of termination of pregnancy for abnormalities of the central nervous system * Death certification of stillbirths and neonatal deaths because of abnormalities * Notifications of abnormalities of babies who live.
There is a differential in the south of Britain, where the proportional decrease is even greater. In many parts of England, particularly in the home counties, the rate of abnormalities of the central nervous system is less than one per 1000. At this level a screening programme that used a fetoprotein might do more harm than good because of action that might be taken on false positive results. Many authorities have abandoned screening for these reasons. Ultrasonography as a screening test for anencephaly has good results, and when modern, high resolution equipment is available spina bifida can be detected. Although the special skills and equipment are currently not always available in ultrasonography clinics, the state of affairs should improve.
Down's syndrome
As explained previously, the risks of Down's syndrome are greater in women over 35, but because most babies are born to women under this age about half of the babies with the syndrome will be missed if age is used as an indicator for fetal chromosome tests. The use of triple biochemical screening with ultrasonography may answer this, although costs will have to be considered. In one health district in south London it costs £38 000 a year to diagnose Down's syndrome in one fetus. Some health authorities would set this against the cost of maintaining a child born with Down's syndrome for the rest of his or her life in an institution, probably over £500 000. The cost of diagnosis, however, comes from one year's budget, whereas the cost of maintenance is spread over many years' budgets; local health authorities are forced into this philosophical financial juggling.
If triple biochemistry screening with ultrasonography is introduced some women considered to be at high risk by age alone will be reallotted to a lower risk group on the results of the triple biochemistry screening. Thus eventually the number of amniocenteses and chromosome examinations will be reduced, but there will be difficulty in persuading conservative groups such as patients and doctors to abandon the age indication for the newer biochemical screening of risk. This subject is full of promise, and new indices may add even further precision to the screening -for example, femur length, which is commonly shorter in fetuses with trisomy 21. At first the antenatal detection of congenital abnormalities may seem to lead only to a nihilistic outcome, but the diagnosis can lead to other lines of management such as the preparation for early paediatric surgery or, in future, to genetic engineering. This is unlikely to be of any help once the embryo has started its development, but work done now on formed embryos can be extrapolated back to research on the oocyte. Here recombinant DNA technology may be used to change the affected part of a chromosome before cell development starts, thus producing a normal fetus. Such technology obviously needs to be controlled by society to help couples who previously had no chance of producing a normal baby.
Conclusions
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